Aspects concerning patient adherence to anti-TNF α therapy in psoriasis: A decade of clinical experience.

Aspects concerning patient adherence to anti-TNFα therapy in psoriasis: A decade of clinical experience. Exp Ther Med. 2019 Dec;18(6):4987-4992 Authors: Mocanu M, Toader MP, Rezus E, Taranu T Abstract Non-adherence to psoriasis treatment has an important impact in controlling chronic disease evolution and the occurrence of systemic comorbidities. Biologic therapy represents a revolutionary treatment, many of the undesirable psychological and socio-economical consequences of conventional topical or systemic therapies being avoided. Nevertheless, the discontinuation of biological therapy may occur due to facts related to the patient, to the lack of good communication between the patient and the physician or to the adverse or paradoxical reactions. We studied the non-adherence reasons to anti-TNFα agents (Infliximab, Adalimumab, Etanercept) used for treating 84 cases with moderate-severe psoriasis. The results of our study over the past 10 years showed a 76.2% adherence rate, lowest in patients treated with Etanercept (70.9%). Relative to the anti-TNF agent used, the highest adherence rate was recorded in Adalimumab (80.8%), followed by Infliximab (76.5%) and Etanercept (70.9%). We have noticed differences between the rates of adhesion to therapy with different anti-TNFα agents, but with no statistical significance. The main adverse effects that occurred during anti-TNFα therapy were: local reaction to the drug, mild infectious events...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research

Related Links:

Dalton Trans., 2020, Accepted Manuscript DOI: 10.1039/C9DT04545G, PaperJoanna Izabela Izabela Lachowicz, Gabriele Dalla Torre, Rosita Cappai, Enrico Randaccio, Valeria Marina Nurchi, Remigiusz RB Bachor, Zbigniew Szewczuk, Lukasz Jaremko, Mariusz Jaremko, Maria Barbara MBP Pisano, Sofia SC Cosentino, Germano Orr ù, Antonella AI Ibba, Joni JM Mujika, Xabier Lopez Mimosine is a non-protein aminoacid with various properties, such as antibacterial, anti-inflammatory, anti-cancer and anti-virus among others. Due to its structure similarity with deferiprone (DFP), mimosine is a potential excellent... The content of this R...
Source: RSC - Dalton Trans. latest articles - Category: Chemistry Authors: Source Type: research
No abstract available
Source: Nursing - Category: Nursing Tags: Department: INFOBYTES Source Type: research
(New York University) Following up on their landmark 2016 study, researchers at NYU Grossman School of Medicine found that a one-time, single-dose treatment of psilocybin, a compound found in psychedelic mushrooms, combined with psychotherapy appears to be associated with significant improvements in emotional and existential distress in cancer patients.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news
ConclusionIn this cohort of middle-aged Danes, diet quality was neither statistically significantly associated with the hazards of late-onset MS diagnosis in the entire sample, nor in sub-groups of current smokers, former smokers or never smokers.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
[African Arguments] The ECOWAS court ruling could have important implications for Sierra Leone, external partners and other countries with similar bans.
Source: AllAfrica News: Pregnancy and Childbirth - Category: OBGYN Source Type: news
Publication date: Available online 27 January 2020Source: International Journal of PharmaceuticsAuthor(s): Lokesh Kaushik, Shubham Srivastava, Anshul Panjeta, Dasharath Chaudhari, Rohan Ghadi, Kaushik Kuche, Ruchi Malik, Simran Preet, Sanyog Jain, Kaisar RazaAbstractDocetaxel (DTX), a widely prescribed anticancer agent, is now associated with increased instances of multidrug resistance. Also, being a problematic BCS class IV drug, it poses challenges for the formulators. Henceforth, it was envisioned to synthesize an analogue of DTX with a biocompatible lipid, i.e., palmitic acid. The in-silico studies (molecular docking a...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Johnson&Johnson Chief Executive Alex Gorsky on Monday faced questions from plaintiffs lawyers over the timing of his sale of company stock, as he testified for the first time in a jury trial over allegations that the company's Baby Powder causes cancer. Gorsky told the jury that he had sold company shares in November 2018, two days after a Reuters reporter contacted the company and summarized in an email her review of documents that showed J&J knew small amou
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Publication date: Available online 27 January 2020Source: Cancer GeneticsAuthor(s): Katsuya Yamamoto, Kimikazu Yakushijin, Mitsuhiro Ito, Hideaki Goto, Ako Higashime, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu MinamiAbstractIn multiple myeloma (MM), MYC rearrangements that result in increased MYC expression are associated with an aggressive form of MM and adverse outcome. However, the consequences of MYC amplification in MM remain unclear. Here, we describe an unusual case of plasma cell leukemia (PCL) harboring MYC amplification on double minute chromosomes (dmin). A 79-year-old woman was initially ...
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
ConclusionWhile a timely work-up of advanced PC patients remains important, delays in treatment initiation due to repeated biopsies, inclusion in a clinical study or transfer to a specialized cancer center appear to be justified in light of the absence of a strong adverse effect of prolonged TTI on prognosis in advanced PC patients.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to evaluate the clinical outcomes, toxicity, and prognostic factors of SBRT combined with gemcitabine plus capecitabine (GEM-CAP) in treating locally advanced pancreatic cancer (LAPC).MethodsA total of 56 patients with LAPC treated with SBRT combined with GEM-CAP were reviewed from October 2010 to October 2016. The median total prescription dose at five fractions was 40  Gy (30–50 Gy). The patients were subjected to two cycles of GEM-CAP before SBRT. GEM-CAP chemotherapy was then offered for four cycles or until disease tolerance or progression. The primary endpoints included overall surviv...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Alopecia | Alopecia Areata | Cancer | Cancer & Oncology | Cardiology | Colon Cancer | Colorectal Cancer | Enbrel | Endocarditis | General Medicine | Heart | Humira | Pancreatitis | Pregnancy | Psoriasis | Psychology | Remicade | Statistics | Study | Thrombocytopenia